Medical Scientists Need Your Help To Find A Better Treatment For Axial Spondyloarthritis
12/12/2016
by
Joseph
People with axial spondyloarthritis have chronic back pain which is usually treated with painkillers and anti-inflammatory medications. Although these provide some relief, the disease continues to progress in some patients while others notice their back pain has returned.
A new research study seeks to give a better understanding of how long-term treatment with the study drug compares to the standard of care treatments provided to these patients.
As a CureClick Ambassador I want to share this information with my readers because it could be helpful for medically treating people who have axSpA. Visit the research sponsor's website to learn more about it.
For those of you whom are not familiar with clinical trials, here's some information that you can use:
What Are Clinical Trials?
Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans.
All investigational devices and medicines must undergo several clinical trials, often times these clinical trials require thousands of people.
Why participate in a clinical trial?
People whom are eligible will have access to new investigational treatments that would be available to the general public only upon approval.
People whom are eligible for clinical trials will also receive study-related medical care and attention from clinical staff at research facilities.
Clinical trials offer hope for many people and gives researchers a chance to find better treatment for others in the future.
Disclaimer: I am not participating in this clinical trial. I am providing this information to my readers as a CureClick Ambasssador. Click on the links below to learn about my relationship with Cureclick and why I'm talking about clinical trials.
Jesus is the Son of God.
***Like us on Facebook!!!***
I'm living fit, healthy and happy(SM). Are you?
Comments
You can follow this conversation by subscribing to the comment feed for this post.